Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III Support Study

被引：6

作者：

Dickinson, Michael J. ^{[1
]}

Cherif, Honor ^{[2
]}

Fenaux, Pierre ^{[3
]}

Mittleman, Moshe ^{[4
]}

Verma, Amit ^{[5
]}

Portella, Maria Socorro O. ^{[6
]}

Burgess, Paul ^{[7
]}

Platzbecker, Uwe ^{[8
]}

机构：

[1] Peter MacCallum Canc Ctr, Div Canc Med, Melbourne, Australia

[2] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden

[3] Univ Paris XIII, Hop Avicenne, AP HP, Bobigny, France

[4] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[5] Einstein Montefiore Canc Ctr, Bronx, NY USA

[6] Novartis Pharmaceutical Corp, E Hanover, NJ USA

[7] Novartis Pharma AG, Basel, Switzerland

[8] Tech Univ Dresden, Carl Gustav Carus, Univ Klinikum, Dresden, Germany

来源：

关键词：

D O I：

10.1182/blood.V128.22.163.163

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

163

引用

页数：7